Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 3/20 | 0.43 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.42 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | JAK1 | P23458 | 2/20 | 0.41 |
| ▸ | TYK2 | P29597 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL913616 | 0.85 | RAB9A (0.43) | DYRK1AGAAHPGDAURKA | |
| SCHEMBL914302 | 0.83 | MAP3K5 (0.51) | ATRJAK3MAP3K5JAK2BTK | |
| SCHEMBL913863 | 0.83 | BUB1 (0.40) | ATRJAK3GRM5DYRK1AJAK2 | |
| SCHEMBL913561 | 0.81 | BRAF (0.49) | DYRK3CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL2695378 | 0.81 | DYRK3 (0.44) | JAK3DYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL913068 | 0.80 | JAK3 (0.62) | JAK3CDK5CDK5R1JAK2JAK1 | |
| SCHEMBL3714460 | 0.80 | JAK3 (0.52) | JAK3DYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL914135 | 0.80 | GABRG2 (0.48) | JAK3DYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL912990 | 0.79 | PIK3CA (0.49) | JAK3DYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL2697897 | 0.77 | SIRT2 (0.43) | JAK3JAK2JAK1TYK2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | claimed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | claimed |
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8367689-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2010129802-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137673-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | ATR 2413/4885JAK3 3/4885GRM5 2587/4885 |
| US-20110005947-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | ATR 2413/4885JAK3 3/4885GRM5 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.